Skip to content

Journal · Neuropharmacology · Updated 15 November 2026

CNS Drugs

Read CNS Drugs articles on DeepDyve. No university library needed.

CNS Drugs, published by Springer Nature, has covered drug treatment of neurological and psychiatric disorders since 1994. Its reviews and research articles look at how medicines for conditions such as epilepsy, pain, depression and anxiety work, how well they perform in trials and what side effects they carry. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of CNS Drugs
Journal cover

CNS Drugs at a glance

Full title
CNS Drugs
Abbreviation (NLM)
CNS Drugs
Publisher
Springer Nature
Print ISSN
1172-7047
Online ISSN (eISSN)
1179-1934
First published
1994
Subjects
Drug Therapy, Neurology, Pharmacology
Access model
Hybrid: subscription, with an open access option
On DeepDyve
Research articles; availability varies by article

Ways to access CNS Drugs

48% of the articles CNS Drugs published from January 1 to November 14, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 48% of CNS Drugs articles published from January 1 to November 14, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
  3. Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
  4. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  5. A library. Your university, hospital or public library may subscribe to CNS Drugs. Check its journal list and whether it offers remote access.
  6. DeepDyve. Read CNS Drugs articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.

Recent CNS Drugs research worth reading

Published June to October 2026. Summaries describe what the authors report.

  1. LitStreamPain medicine · Trigeminal neuralgia

    Emerging Pharmacological Strategies for Trigeminal Neuralgia

    This review covers clinical evidence for newer drug approaches to trigeminal neuralgia, including CGRP receptor inhibition, TRPV1 channel activation and desensitization, new sodium channel blockers and botulinum toxin, and the authors conclude that larger well-controlled studies are needed for a definitive answer.

    Chichorro et al. · CNS Drugs, published online June 29, 2026 · DOI 10.1007/s40263-026-01310-y

  2. LitStreamEpilepsy · Cognitive side effects

    Cognitive Side Effects of Antiseizure Medications in Adults with Epilepsy: An Update with a Focus on New Therapeutic Agents

    This review covers studies from 2009 to 2025 on the cognitive effects of antiseizure medications in adults, reporting generally favourable profiles for newer agents such as lacosamide, brivaracetam and cannabidiol at recommended doses, and consistently higher cognitive risks with older drugs, topiramate and zonisamide.

    Mula · CNS Drugs, published online September 9, 2026 · DOI 10.1007/s40263-026-01331-7

  3. LitStreamPsychopharmacology · Psychedelic microdosing

    Efficacy and Safety of Psychedelic Microdosing on Psychological Outcomes in Healthy Adults: A Systematic Review and Meta-analysis

    Reviewing 24 studies with 3,681 healthy adults, the authors found that randomized trials of psilocybin and LSD microdosing showed no clear immediate reduction in depressive, anxiety or stress symptoms compared with placebo, and that adverse event risks were similar between treatment and control.

    CNS Drugs, October 2026 · DOI 10.1007/s40263-026-01325-5

  4. LitStreamPain medicine · Cancer pain

    Opioid Add-On Combination Therapy for Cancer Pain: Pharmacological Rationale, Clinical Evidence, and Future Directions

    This review covers adding a low dose of a second opioid, mainly methadone at 3 to 15 mg a day, to an ongoing opioid regimen for cancer pain, reporting responder rates of 50 to 94% and pain score reductions of 2 to 3 points within 7 to 15 days.

    CNS Drugs, October 2026 · DOI 10.1007/s40263-026-01329-1

See every CNS Drugs article on DeepDyve

Questions about CNS Drugs

How can I read CNS Drugs articles without a subscription?

48% of CNS Drugs articles published from January 1 to November 14, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read CNS Drugs articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for CNS Drugs?

CNS Drugs isn’t abbreviated: its NLM (PubMed) abbreviation is simply CNS Drugs.

What is the ISSN of CNS Drugs?

The print ISSN is 1172-7047 and the online ISSN is 1179-1934.

Is CNS Drugs open access?

CNS Drugs is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 14, 2026, 39 of 82 CNS Drugs articles (48%) carry a Creative Commons license, per Crossref.

CNS Drugs articles on DeepDyve are licensed from Springer Nature. Journal facts as of 15 November 2026.

Start reading CNS Drugs today

One month free, then less than $2 a day. CNS Drugs, plus millions of articles from thousands of journals.

Start free month

Like this: